Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U2CV
|
|||
| Former ID |
DNC001459
|
|||
| Drug Name |
Trapidil
|
|||
| Synonyms |
trapidil; Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute coronary syndrome [ICD-11: BA41] | Phase 4 | [1] | |
| Coronary artery disease [ICD-11: BA80; ICD-10: I25.1, I25.4] | Phase 4 | [1] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Investigative | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H15N5
|
|||
| Canonical SMILES |
CCN(CC)C1=CC(=NC2=NC=NN12)C
|
|||
| InChI |
1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3
|
|||
| InChIKey |
GSNOZLZNQMLSKJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 15421-84-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
866458, 5659229, 7848283, 8153404, 11112623, 11467040, 11468160, 11486770, 14745540, 14748788, 29224573, 47810921, 47959939, 48110614, 48259417, 49699027, 50057667, 50086436, 50100500, 56365869, 57322829, 74813390, 85787550, 88858725, 92126029, 92133451, 93815048, 103371622, 103914683, 104309497, 105640614, 117431105, 121363700, 124799773, 125432948, 126922620, 127999928, 134340574, 134340639, 134991679, 137248780, 144204129, 162249201, 162796478, 169428974, 170465770, 175612102, 178126772, 179149421, 184547380
|
|||
| ChEBI ID |
CHEBI:32254
|
|||
| SuperDrug ATC ID |
C01DX11
|
|||
| SuperDrug CAS ID |
cas=015421848
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor receptor 3 (FGFR3) | Target Info | Inhibitor | [2] |
| Platelet-derived growth factor receptor (PDGFR) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| MicroRNAs in cancer | ||||
| Bladder cancer | ||||
| Central carbon metabolism in cancer | ||||
| Panther Pathway | FGF signaling pathway | |||
| Reactome | FGFR3 mutant receptor activation | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Endochondral Ossification | ||||
| Bladder Cancer | ||||
| Neural Crest Differentiation | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00914420) Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide Stent Versus Taxus . U.S. National Institutes of Health. | |||
| REF 2 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 3 | Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.